European journal of clinical investigation
-
Eur. J. Clin. Invest. · Dec 2022
Review Meta AnalysisIncidence of immune checkpoint inhibitor mediated cardiovascular toxicity: A systematic review and meta-analysis.
Immune checkpoint inhibitors (ICI) are a novel class of anti-cancer therapy becoming increasingly associated with fatal cardiovascular toxicities (CVTs). The aim is to determine the incidence of CVTs in cohorts treated with ICIs as sole anti-cancer therapy. ⋯ ICI-mediated CVTs are rare and potentially fatal. The role of CV risk factors in their development remains unclear.
-
Eur. J. Clin. Invest. · Dec 2022
Multicenter StudyEffect of PCSK9 inhibitors on cholesterol remnants and lipid residual risk: the LIPID-REAL Registry.
Monoclonal antibodies that inhibit the proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low-density lipoprotein cholesterol (LDLc) by 55%, regardless of baseline treatments. Nonetheless, the effect of other lipid parameters, such as cholesterol remnants or, the so-called lipid residual risk, is unknown. ⋯ This multicenter and retrospective registry of real-world patients treated with PCSK9 inhibitors demonstrates a positive effect on cholesterol remnants and lipid residual risk beyond LDLc reductions.